Pregnancy test Sodium Electrolytes Ammonia Pregnancy Test Pregnancy Test Serum Levels At steady At steady state Two levels to establish dose, 4 weeks apart 3-6 months As clinically indicated As clinically indicated As clinically indicated Longitudinal Monitoring 3 Once At 3months: Every 3 months Monthly for 3 months: months BUN for the 1st year of CBC SCr therapy: LFTs Weight TSH Albumin CBC Electrolytes LFTs BUN Albumin SCr Sodium Every 6 --- --- months Every 12 Weight Weight CBC months CBC LFTs LFTs Albumin Albumin Electrolytes Sodium BUN BP* SCr Bone density* FBG * Fasting lipids* *If there are clinical risk factors BP blood pressure; BUN blood urea nitrogen; CBC complete blood count; ECG – – – – echocardiogram; FBG fasting blood glucose; FLP fasting lipid profile; LFTs liver – – – function tests; SCr serum creatinine; TSH thyroid stimulating hormone; VPA valproic – – – acid and derivatives Results Unit Baseline 1Q2017 2Q2017 3Q2017 4Q2017 YTD 90% 90% 90% 90% 90% Target 79% Laboratory (FY2016) 60% 81% Parameters Actual
Pregnancy test Sodium Ammonia Pregnancy Test Electrolytes Pregnancy Test Serum Levels At steady 3-6 months As clinically indicated At steady state As clinically indicated Two levels to establish dose, 4 weeks apart As clinically indicated Longitudinal Monitoring 3 months Once At 3months: BUN SCr TSH Every 3 months for the 1st year of therapy: Weight CBC LFTs Albumin Sodium Monthly for 3 months: CBC LFTs Albumin Electrolytes BUN SCr Every 6 months --- --- Every 12 months Weight Weight CBC LFTs Albumin Sodium BP* Bone density* FBG * Fasting lipids* CBC LFTs Albumin Electrolytes BUN SCr *If there are clinical risk factors BP – blood pressure; BUN – blood urea nitrogen; CBC – complete blood count; ECG – echocardiogram; FBG – fasting blood glucose; FLP – fasting lipid profile; LFTs – liver function tests; SCr – serum creatinine; TSH – thyroid stimulating hormone; VPA – valproic acid and derivatives Results Unit Baseline 1Q2017 2Q2017 3Q2017 4Q2017 YTD Target Laboratory Parameters 79% (FY2016) 90% 90% 90% 90% 90% Actual 60% 81%
2017Q1.docx